EnlitenAI

Built an AI platform for personalizing the treatment of seizures/Epilepsy using wearables for continuous monitoring of neurological indicators.

Our platform offers data monetization opportunities.

1. Product readiness: Clinical Study at UCHealth (Colorado) completed and is a strong validation of our product.
2. Commercialization: Starts in Q3 2024
3. Strong market traction with
A. Neurology Centers: UCSF, UCHealth, Baylor, Univ of New Mexico
B. Devices - Apple, Emotiv, Neureka & Dreem3
D. EEG Annotation partner - TALOS
E. Endorsement by Epilepsy Foundation & invitation to be on their dtRRE panel
4. Reimbursement Strategy guidance created
5. Phased approach to FDA Regulatory Strategy (Class I in Q2'24 and Class II in Q4'24) - Software Assisted Medical Device

Neurologists are unable to build personalized treatment plans owing to the unpredictable nature of seizures and the lack of insights on patient specific responses to medications.  Drug titration is trial-and-error based and extremely long.  This leads to the skyrocketing cost burden for insurance carriers.  Today, wearable OEMs are able to detect seizures, but unable to synthesize real world evidence and optimize the treatment regimen is unaddressed today. They fall short.

EnlitenAI is addressing the unmet needs in personalizing the management of seizures, especially drug titration.

The EnlitenAI platform aids seizure burden calculations, informing decisions of dose adjustment or drug substitution, potentially reducing delays in care and shortening titration cycles. In later phases, the platform will sport features pertinent to drug/dose recommendations further alleviating the “trial-and-error” problem pervasive in epilepsy management.

Our commercialization strategy is based on a SaaS monetization model. Our Go-to-market strategy is B2B, wherein each neurology center is treated as a named account. The Neurologists advocate the use of our platform by prescribing Neuroliten to the patients.

The Neurology centers get reimbursed using Remote Therapeutic Monitoring codes, that already exist, by the Payers. Their incentive is to expand their practice, more frequent billing & see more patients for better health outcomes.

Neurology centers have an incentive to work with us they generate a new stream of revenue.

Epilepsy Foundation/Danny Did Foundation Accelerator
IIT Startups
LifeX-Jumpstart Ventures
Innosphere Ventures
Aurelia Ventures